Logo

Shire's Takhzyro (lanadelumab-flyo) Receives FDA Approval Novel Hereditary Angioedema (HAE) in Age ≥12yrs

Share this

Shire's Takhzyro (lanadelumab-flyo) Receives FDA Approval Novel Hereditary Angioedema (HAE) in Age ≥12yrs

Shots:
  • Approval is based on four clinical studies including P-III HELP (Hereditary Angioedema Long-term Prophylaxis) study (N=125) for 26 wks- administering Takhzyro 300mg Q2W- Q4W and 150 mg Q4W
  •  HELP results (Takhzyro vs PBO): No attack (44% vs 2%); 87% reduction in monthly attacks; post hoc (77% vs 3%) attack free; attacks requiring acute treatment (74% vs 87%-) and moderate or severe attacks (70% to 83%)
  • Takhzyro receives Orphan drug designation. Shire acquired Takhzyro from Dyax in Jan’16 for $5.9B
/ | Ref: Shire| Image: EHSCareers

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions